

EUROPEAN JOURNAL OF NEUROLOGY

Volume 29, Supplement 1, June 2022

Abstracts of the 8th Congress of the European Academy of Neurology

Vienna, Austria

Disclaimer:

This abstract volume has been produced using author-supplied copy. Editing has been restricted to some corrections of spelling and style where appropriate. No responsibility is assumed for any claims, instructions, methods or drug dosages contained in the abstracts: it is recommended that these are verified independently.



HEAD OFFICE: Breite Gasse 4/7
1070 Vienna, Austria

PHONE: +43 1 889 05 03
FAX: +43 1 889 05 03 13
E-MAIL: headoffice@ean.org
WEB: www.ean.org

ISSN 1468-1331 (202206)29:6+1

- Raccagni, C. 615, 917
 Rachão, A. 256, 513, 761, 871
 Racovita, S. 906
 Radaelli, M. 64
 Rademacher, M. 264
 Radovic, M. 904
 Rafee, S. 839, 859
 Raffa, G. 914
 Raffa, S. 94
 Raggi, A. 414
 Ragonese, P. 234, 488, 781
 Rahimpour Moradi, A. 914
 Rahmani, M. 510
 Raimondo, F. 126, 128
 Raimundo, R. 878
 Rajda, C. 852, 861
 Rajdová, A. 664
 Rajić, S. 876
 Rajkovača Latić, I. 899
 Raket, L. 537
 Rakhimbaeva, G. 850, 878
 Rakhmatullaeva, S. 752
 Rakocevic-Stojanovic, V. 229, 823, 873
 Rakusa, M. 108, 125, 670, 850
 Rakusa, S. 125, 850
 Rama Raju, V. 623
 Ramazanoglu, L. 850
 Rambousek, J. 912
 Ramchandren, S. 299, 845
 Ramió i Torrentà, L. 815, 858
 Ramió-Torrentà, L. 630
 Ramirez-Moreno, J. 884
 Ramírez Toledo, R. 709, 843, 849, 917
 Ramiro, J. 880
 Ramm, M. 876
 Ramo-Tello, C. 286, 475
 Ramos, C. 666, 667
 Ramos, L. 392
 Ramos, M. 892
 Ramos Fransi, A. 227
 Ramos Reyes, V. 882, 905
 Rancz, R. 392
 Randerath, W. 833
 Randi, A. 775
 Raniero, A. 194
 Ranjan, A. 856, 870, 910
 Ransmayr, G. 917
 Ranxha, E. 619
 Ranzani, M. 505
 Rao, R. 589, 723, 854
 Rapillo, C. 844
 Raposo, S. 882
 Rapti, A. 819
 Raquel, S. 211
 Rascol, O. 440, 446, 450, 451, 619
 Rascunà, C. 616
 Rashed, L. 784
 Rasini, E. 614
 Raskurazhev, A. 878, 881, 882
 Rass, V. 18, 722
 Rasulova, D. 596
 Rasul, S. 574
 Ratajczak-Tretel, B. 660
 Rathakrishnan, R. 335
 Rath, J. 138
 Ratti, A. 90, 276
 Rauser, B. 151, 351
 Ravaglia, S. 231, 654
 Ravanidis, S. 448
 Ravenscroft, G. 58, 162
 Ravey, F. 307
 Ravits, J. 343
 Ravnholz Jensen, H. 126, 128
 Rawlings, A. 494
 Ray Chaudhuri, K. 613
 Raymond, A. 911
 Raynaud, S. 227
 Razek, A. 202
 Razumnikova, O. 258
 Razzino, E. 481
 Realmuto, S. 488
 Rebella, S. 462
 Rebelo, O. 478, 818
 Rebollo, B. 884
 Redko, O. 705
 Redmond, J. 906
 Reeta, K. 546
 Regalbuto, S. 280
 Regelberger, G. 324
 Régo, A. 544, 577
 Rego, R. 515, 566, 571, 728, 732
 Rego-García, I. 251
 Regondi, S. 686
 Regragui, W. 773, 843, 852
 Reguig, A. 863
 Reichenbach, A. 596
 Reichen, I. 302
 Reichmann, H. 768
 Reilly, C. 890
 Reilly, K. 463
 Reilly, M. 34, 162, 231, 656, 826
 Reimão, S. 655, 814
 Reindl, M. 237
 Reinhard, C. 318, 453, 602, 683
 Reis Carneiro, D. 130, 131, 325
 Reiser, M. 543
 Reishofer, G. 862
 Reitner, A. 340
 Rejane Santiago Dias, K. 895
 Rejdak, K. 75, 349, 848, 864, 900, 902
 Reka, E. 856
 Rekik, A. 913
 Rektor, I. 571, 578
 Religa, D. 146, 692, 693
 Rémi, J. 339, 733
 Remlinger, J. 303
 Renjen, P. 744, 868
 Renken, R. 101
 Renna Linton, L. 453
 Rentzos, M. 878, 906, 907
 Renu, A. 804
 Repice, A. 864
 Resa Serrano, E. 425
 Resende Costa Pimenta, M. 889, 895
 Resulova, A. 539
 Retter, D. 905
 Reuber, M. 891
 Reuner, U. 356
 Reuther, K. 498
 Revenco, N. 708, 868
 Revendova, K. 797
 Revuelta, A.F. 842
 Rey, J. 798
 Reyes, M. 576
 Reyes-Calavera, A. 850, 872
 Reyes Leiva, D. 227
 Reyes-Sosa, L. 703, 880
 Reynders, T. 816
 Ribacoba Díaz, C. 879, 903, 908, 912
 Ribas, L. 214
 Ribeiro, A. 883, 895
 Ribeiro, C. 638
 Ribeiro, J. 750
 Ribeiro, L. 389, 844
 Ribigan, A. 842, 872, 909
 Ribizzi, G. 634
 Ribolla, F. 91
 Ricard, D. 207
 Ricceri, R. 390
 Ricci, D. 238
 Ricci, F. 479
 Ricci, G. 107, 600, 913
 Rich, P. 532
 Richardson, D. 532
 Richardson, M. 110
 Richter, D. 753
 Rider, F. 124, 200, 356, 580, 853
 Ridley, B. 170
 Riedhammer, K. 581
 Riedl, K. 204, 220, 281, 793
 Riedner, B. 196
 Rigoni, E. 818
 Rigual, R. 333, 540
 Rijnsburger, M. 204
 Riley, C. 864
 Rinaldi, D. 163, 454, 623
 Rinaldi, R. 166, 361
 Rinaldi, V. 456
 Rio, J. 347
 Riolo, J. 203, 283
 Rios, D. 838, 883
 Ríos Patiño, D. 892
 Risi, B. 316, 487, 904
 Risi, M. 725, 869
 Risitano, A. 882
 Riso, V. 868
 Rispens, T. 217
 Ristolainen-Kotimäki, S. 610
 Ristori, G. 456
 Rito, M. 859
 Ritter, K. 302
 Ritter, M. 722
 Ritter, S. 272
 Riva, A. 201
 Riva, B. 545
 Riva, N. 275, 345, 537
 Rivoirard, R. 674
 Rizos, A. 613
 Rizvanov, A. 425
 Rizzardi, A. 317, 778
 Rizzetti, M. 898
 Rizzo, F. 238, 358
 Rizzo, G. 769, 896
 Roa, J. 413
 Robert, A. 567
 Roberto, P. 211
 Roberts, M. 59
 Robertson, D. 284, 628, 631, 634
 Robertson, N. 288
 Robieson, W. 178
 Robijns, J. 327
 Robinson, H. 122
 Robles Cedeño, R. 815, 858
 Robles, R. 900
 Robson, J. 334
 Roca, M. 677
 Rocca, C. 353
 Rocca, M. 30, 50, 51, 63, 64, 84, 118, 155, 156, 195, 261, 263, 294, 473, 476, 633, 680
 Roccatagliata, L. 462, 634
 Rocchi, C. 523
 Roch, E. 895
 Rocha, A. 735
 Rocha, C. 894, 910
 Rocha, G. 158
 Rocha, H. 566, 571, 732
 Rocha, I. 130, 131
 Rocha, J. 438, 440, 446, 450, 451, 619, 620
 Rocha, M. 383
 Rocha, R. 389, 844

diagnosis of papilledema with positive PCR to VZV in CSF (which is exceptional). We remark the importance of the early diagnosis to start a prompt treatment with both systemic acyclovir and topical or systemic corticosteroids.

Disclosure: Nothing to disclose.

EPO-588

The intestinal epithelium is one of the loci where primary HIV occurs

S. Rakhmatullaeva, M. Muminova, D. Abdurakhimova,
S. Shokhimardonov
Tashkent Medical Academy, Taschkent, Uzbekistan

Background and aims: The intestinal epithelium is one of the loci where primary HIV occurs.

Methods: 746 children under the age of 18 were studied. The children were divided into 3 groups: the 1st group included 261 HIV-infected children with acute diarrhea, the 2nd group included 238 HIV-infected children without diarrhea, and the 3rd group included 247 children with acute diarrhea without HIV infection. The diagnosis was made on the basis of clinical, serological, bacteriological, immunological, virological research methods.

Results: Violation of the intestinal microbiocenosis was noted in all children of the 1st group, in 94.1% of the 2nd and in 88.7% of the 3rd group. *Bacteroides* spp., <10¹⁰cfu/g in most cases was observed in the 1st group, compared with the 1st group in the 2nd group by 1.5 times, and in the 3rd group 1.5 times less often (68, 6%, 57.9% and 38.8%, respectively, p<0.05). Indicators of *Bifidobacterium* spp. <10⁹CFU/g, *Lactobacillus* spp. <10⁷CFU/g and *E. coli* lac+ <10⁷ CFU/g in comparable groups, there were no significant differences, only among the 1st and 3rd groups there were significant differences (p>0.05).

Conclusion: In all HIV-infected children with acute diarrhea, a violation of the microbiocenosis of the intestine develops and profound changes are noted in the indicators of the obligate microflora.

Disclosure: Nothing to disclose.

EPO-589

Three-dose Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy: a case report

K. Varmopompi, K. Wannop, L. Mantoan
King's College Hospital NHS Foundation Trust, London, United Kingdom

Background and aims: We report a case of Progressive Multifocal Leucoencephalopathy (PML) on a background of primary lymphopenia, treated with Pembrolizumab, a humanized monoclonal anti-programmed cell death protein 1 (PD-1) antibody.

Methods: A 67-year-old gentleman, previously independent, presented with rapid-worsening cognitive decline, bulbar weakness with severe dysarthria and dysphagia and marked upper and lower limb ataxia. His MRI-brain showed a confluent area of signal abnormality involving the posterior fossa structures, with marked low T1 signal, and without any mass effect, which were atypical for a neoplastic process. The patient received extensive diagnostic work up with CSF analysis including flow-cytometry. Paraneoplastic and autoimmune screen was negative in the CSF and bloods. He was found to be pan-lymphopenic attributed to a primary immunodeficiency. There was no lymphadenopathy or malignancy in the PET scan. Infective screen including HIV screen was negative. CSF was positive for JC-virus with low viral load (623 copies/ml).

Results: The patient continued to deteriorate despite prolonged treatment with steroids. To guide the diagnosis of PML, his CSF was tested for JCV antibodies, which were positive. The patient was diagnosed with PML and was treated with 3 doses of Pembrolizumab 1mg/kg with 6 weeks intervals. He had significant subjective and objective improvement 6 months in total after the first dose especially involving his finger-to-nose dysmetria and his dysarthria.

Conclusion: This is a case of PML in the context of idiopathic pan-lymphopenia. Our results show that pembrolizumab is a promising treatment for PML and it should be further evaluated with randomised-controlled trials.

Disclosure: Nothing to disclose.